Drugs / 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha)
15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06756269 | Jan → Oct 2025 overdue | human papilloma virus infection, human papillomavirus-related squamous cell carcinoma, intraepithelial neoplasia, viral sexually transmitted disease | Shanghai Bovax Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) | “15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha)” NCT06756269 ↗ |
| Modality | Vaccine | “15-valent Human Papillomavirus Recombinant Vaccine” NCT06756269 ↗ |
| Route | Intramuscular | “intramuscular into the upper arm deltoid muscle” NCT06756269 ↗ |